Table 1.
Baseline demographics and dependent variables by group (N = 506).
| All |
HIV−/COC− |
HIV+/COC− |
HIV+/COC+ |
HIV−/COC+ |
|
|---|---|---|---|---|---|
|
M (SD) |
M (SD) |
M (SD) |
M (SD) |
M (SD) |
|
|
N (%) |
n (%) |
n (%) |
n (%) |
n (%) |
|
| Variable | N = 506 | n = 200 | n = 100 | n = 106 | n = 100 |
| Age | 36.18 (9.53) | 34.34 (8.98) | 34.60 (10.69) | 40.82 (8.66) | 36.54 (8.64) |
| Sex | |||||
| Male | 256 (50.7) | 102 (51.0) | 35 (35.0) | 45 (43.5) | 74 (74.0) |
| Female | 250 (49.4) | 98 (49.0) | 65 (65.0) | 61 (57.5) | 26 (36.0) |
| Ethnicity | |||||
| Caucasian | 57 (11.3) | 22 (11.0) | 5 (5.0) | 12 (11.3) | 18 (18.0) |
| African American | 313 (61.9) | 116 (58.0) | 73 (73.0) | 76 (71.7) | 48 (48.0) |
| Haitian | 13 (2.6) | 7 (3.5) | 5 (5.0) | 1 (0.9) | 0 (0.0) |
| Hispanic/Latino Caucasian | 96 (19.0) | 41 (20.5) | 13 (13.0) | 15 (14.2) | 27 (27.0) |
| Hispanic/Latino Black | 12 (2.4) | 5 (2.5) | 2 (2.0) | 2 (1.9) | 3 (3.0) |
| Other | 15 (3.0) | 9 (4.5) | 2 (2.0) | 0 (0.0) | 4 (4.0) |
| Income (monthly) | |||||
| US$0–US$500 | 215 (42.7) | 75 (37.5) | 34 (34.0) | 47 (44.3) | 59 (60.2) |
| US$500–US$1000 | 194 (38.5) | 57 (28.5) | 54 (54.0) | 52 (49.1) | 31 (31.6) |
| US$1000–US$5000 | 89 (17.7) | 64 (32.0) | 12 (12.0) | 7 (6.6) | 6 (6.1) |
| US$5000–US$10000 | 4 (0.8) | 2 (1.0) | 0 (0.0) | 0 (0.00) | 2 (2.0) |
| US$10000+ | 2 (0.4) | 2 (1.0) | 0 (0.0) | 0 (0.00) | 0 (0.0) |
| Outcomes Plaque | |||||
| No | 373 (74.6) | 153 (78.1) | 81 (81.0) | 70 (66.7) | 69 (69.7) |
| Yes | 127 (25.4) | 43 (21.9) | 19 (19.0) | 35 (33.3) | 30 (30.3) |
| CV Risk | 6.45 (1.43) | 6.05 (1.30) | 6.36 (1.42) | 6.99 (1.44) | 6.79 (1.46) |
| Predictors | |||||
| Waist circumference | 95.40 (16.39) | 96.17 (17.35) | 96.16 (17.73) | 91.75 (16.15) | 96.98 (12.51) |
| sCD14 (ng/mL) | 1786.11 (521.00) | 1677.77 (381.01) | 1973.07 (412.48) | 1994.57 (675.13) | 1629.68 (499.51) |
| sCD163 (ng/mL) | 611.53 (363.77) | 525.15 (269.14) | 747.89 (417.52) | 729.62 (412.54) | 543.37 (360.89) |
| IL-1α (pg/mL) | 68.55 (76.56) | 67.33 (72.17) | 61.80 (58.68) | 73.62 (102.98) | 72.67 (65.93) |
| IL-6 (pg/mL) | 7.73 (15.82) | 6.40 (7.30) | 9.14 (25.55) | 7.21 (8.99) | 9.07 (14.96) |
| TNF-α (pg/mL) | 18.70 (22.49) | 10.60 (9.10) | 30.44 (35.83) | 33.24 (22.54) | 10.12 (8.51) |
| VEGF (pg/mL) | 79.23 (96.45) | 62.84 (67.82) | 106.28 (108.14) | 96.00 (137.22) | 70.34 (79.78) |
| LPS (pg/mL) | 154.05 (51.48) | 141.42 (38.26) | 167.68 (59.06) | 191.62 (60.05) | 130.90 (31.20) |
| CRP (mg/L) | 1964.41 (787.53) | 1965.85 (771.84) | 2170.10 (749.33) | 1988.66 (802.54) | 1739.70 (793.82) |
| CD309+CD34+ (% of MG) | 0.40 (0.90) | 0.33 (0.75) | 0.33 (0.36) | 0.66 (1.69) | 0.42 (0.63) |
| CD309+CD133+ (% of MG) | 11.12 (193.57) | 3.26 (35.90) | 1.15 (4.54) | 0.92 (1.24) | 41.94 (405.76) |
| Lymphocytes (%) | 27.92 (9.76) | 28.47 (8.96) | 30.26 (10.52) | 26.28 (9.27) | 25.78 (10.28) |
| Monocytes (%) | 5.61 (2.15) | 5.43 (1.83) | 5.79 (2.32) | 5.83 (2.42) | 5.63 (2.34) |
MG: monocyte gate; CV: cardiovascular; IL-6: interleukin-6; TNF-α: tumor necrosis factor; VEGF: vascular endothelial growth factor; LPS: lipopolysaccharide; CRP: C-reactive protein.
Note. Group combinations presented as (HIV status/cocaine status).